The Nativis Voyager® ulRFE™ system is a non-invasive medical device. It is the first of many product expressions of the company’s underlying ulRFE platform technology. Demonstrating safety and showing promise in pre-clinical and clinical trials, the Nativis Voyager® has potential treatment applications in a wide range of diseases, including cancer, chronic pain, inflammatory, among others. The Nativis Voyager device is first being evaluated for the treatment of recurrent glioblastoma multiforme (rGBM) brain tumors in human clinical trials.
Note: Nativis Voyager ulRFE System for rGBM is an investigational medical device. Limited by Federal (or United States) law to investigational use only.
Every molecule has a specific and unique electrostatic surface potential. Electrostatic surface potential is a critically important property of a molecule; it is a key factor in how a molecule interacts with (and in) a biological system. For the first time ever, the ultra-low radio frequency energy (ulRFE) profiles produced by changes in molecular electrostatic surface potential can be measured and recorded by our ‘Super Conducting Quantum Interference Device’ (SQUID)-based technology (more info on SQUID>). Transducing these highly precise ulRFE profiles (cognates) into biological systems have been show to produce precise biological responses. It is theorized that transduction of these cognates induces selective charge transfer in a defined bioactive target, thus altering cell dynamics, which can produce biological effects.